Shandong Weigao Group Medical Polymer Company Limited (WEIGAO GROUP) disclosed a repurchase of 140,000 H-shares on 16 October 2026 via on-market transactions on the Hong Kong Stock Exchange.
• Transaction details – Volume: 140,000 shares, equivalent to 0.0031% of the company’s issued share capital (excluding treasury shares) prior to the buy-back. – Price range: HKD 3.345 to HKD 3.365 per share; volume-weighted average price: HKD 3.3543. – Aggregate consideration: HKD 0.47 million.
• Capital structure after the transaction (16 October 2026) – Issued shares (excluding treasury shares): 4.45458 billion, down from 4.45472 billion. – Treasury shares: 67.75 million, up from 67.61 million. – Total issued shares (including treasury shares): unchanged at 4.52233 billion.
• Repurchase mandate utilisation – Shareholders authorised a maximum repurchase of 446.46 million shares at the annual general meeting on 29 May 2026. – Cumulative repurchases under the mandate now total 10.42 million shares, representing 2.33% of the company’s issued shares at the mandate date. – A 30-day moratorium on new share issues or treasury-share disposals runs until 16 November 2026.
The board confirmed that the share repurchase complied with all relevant Hong Kong Listing Rules and regulatory requirements.
Comments